Polycythemia vera (PV) causes thrombosis. Erythrocytosis and cell adhesiveness are
responsible for thrombosis. JAK2V617F causes inflammation and autoimmunity; however …

The pathogenesis of thrombosis in patients with polycythemia vera (PV) results from a
complex interplay of patient-and disease-related variables. According to age and previous …

Background Thrombo-hemorrhagic complications cause significant morbidity and mortality
in patients with polycythemia vera (PV). Objectives To assay and correlate inflammatory …

The clinical courses of polycythemia vera (PV) and essential thrombocythemia (ET) are
characterized by thrombohemorrhagic diathesis. Several groups have suggested an …

Thrombotic and cardiovascular events are among the leading causes of death for patients
with polycythemia vera (PV), and thrombosis history is a key criterion for patient risk …

Background JAK2 mutation status is a well-known risk factor for thrombosis in patients with
myeloproliferative neoplasms. However, the clinical usefulness of JAK2 V617F allele burden …

Studies have shown that the clinical impact of Janus kinase 2 (JAK2) inhibitors in primary
myelofibrosis patients is due to the regulation of cytokine levels, suggesting that cytokine …

Background: Thrombosis is the main cause of morbidity and mortality in pts with
Polycythemia Vera (PV). Current risk stratification is based on 2 variables: age> 60y and …

In polycythemia vera, gender has recently been shown to influence the JAK2 V617F allele
burden, but its effect on the disease phenotype is unknown. This issue was investigated …

The aim of this study was to determine whether the burden of JAK2 V617F allele correlated
with major clinical outcomes in patients with polycythemia vera (PV). To this end, we …